February 15, 2019 7:45am

Recent clinical misses (CLBS and SLDB), volatility, low volume and sentiment qualms add to the risk of share pricing also, the IBB has also been up five (5) up sessions in a row without indicating in the pre-open …

Follow the bouncing share pricing

Pre-open indications:  1 BUY, 1 SELL and 3 TRADEs


You can lead a horse to water but you can't make him drink' is a proverb which means that you can give investors an opportunity but can’t force them to take it.

Presenting alternative hypotheses clarifies material facts and evidence available to investors. “Devil’s Advocacy” also provides greater confidence that the current sector outlook will hold-up to close scrutiny!


U.S. stock index futures flipping and sliding

Dow futures are UP +0.08% (+20 points) and NASDAQ futures are UP +0.03% (+2 points)


U.S. futures are flipping to the upside - barely;

European markets mixed after weak US data; Spain set to call snap election;

Asian stocks decline amid fears of slowing US economy


Data docket: industrial production numbers out at 9.15 a.m. ET and consumer sentiment out at 10 a.m. ET.


Friday’s indications in the pre-market:

The iShares Nasdaq Biotechnology (IBB) is NOT indicating

The SPDR S&P Biotech ETF (XBI) is indicating a NEGATIVE -0.02% DOWNSIDE

The Health Care Select Sector SPDR ETF (XLV) is NOT indicating

The iShares Russell 2000 (IWM) is indicating a POSITIVE +0.0195% UPSIDE



TGIF; I think I will take an Aleve now as the pain could be coming – does it treat sector, market and political psychosis?

Politics remains the focus as President Trump is due to speak in the White House Rose Garden at 10 a.m. ET.

TGIF; I think I will take an Aleve now as the pain could be coming – does it treat sector, market and political psychosis?

Does an aftermath define a prelude (?); an indication is a fragment of information or even an observation whose sole provision is that it provides insight into a likely course of action

From last night, “buzz kill; the sector takes a hit as the uncertainty and risk of clinical data <Caladrius Bioscience (CLBS -$1.34 or -25.09%)> resides front and center as the sector reacts to uncertainties. It’s not totally about putting “lipstick on a pig” but, diabetes’ clinical trials haven’t produced a lot of recent success.”

  • Range of last night’s 16 upside was +0.26% (BCLI) to +6.02% (VCEL) while the 28 downside ranged from -0.09% (VYGR) to -25.09% (CLBS) with 1 flat close (CLLS).
  • 4 out of the 16 upside had higher (than the 3 month average) volume
  • 3 out of the 28 downside experienced greater volume (than the 3 month average)


Companies in my headlights – It’s your decision; I provide an idea and context:

bluebird bio (BLUE) closed down -$1.33 to $134.29 after Wednesday’s +$0.36 to $135.62 and has seen $130.75 (2/8) and $130.16 (1/30) twice while starting January at $99.50. RICH and a candidate before quarterly results – Maintaining SELL;

I hate to have to harp on specific companies so often: as I have stated this peer group is a trading vehicle …

  • CRISPER Therapeutics (CRSP) closed down -$0.18 to $30.93 after Wednesday’s -$0.53 to $31.11, Tuesday’s +$0.51 and Monday’s +$0.74. CRSP has a positive +$0.21 or +0.68% aftermarket indication. The overbought become the oversold and bounce back – TRADE;
  • Editas Medicine (EDIT) closed down -$0.09 to $19.86 after Wednesday’s-$0.34 to $19.95, Tuesday’s +$0.32 after Monday’s +$0.22. EDIT has a negative -$0.01 or -0.05% aftermarket indication – TRADE;
  • Intellia Therapeutics (NTLA) closed up +40.14 to $13.89 after Wednesday’s -$0.17 to $13.75, Tuesday’s +$0.21 and Monday’s +$0.27 without any indication – TRADE;

Solid Biosciences (SLDB) closed down -$0.56 to $7.77 after Wednesday’s +$0.74 to $8.33 and has a positive +$0.23 or +2.96% aftermarket indication following a 67.82 % dive based on 2/7’s evaluation of the SGT-001 in a DMD (Duchenne muscular dystrophy) indication which were NOT very encouraging. A trading TOY and NO new news to back-up ANY upside post the FALL from the data release – SELL to BUY;


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.